The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Major Clinical Outcomes in Antiretroviral Therapy (ART)–Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study
Open accessAbstract
BACKGROUND: The SMART study randomized 5,472 human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts >350 cells/microL to intermittent antiretroviral therapy (ART; the drug conservation [DC] group) versus continuous ART (the viral suppression [VS] group). In the DC group, participants started ART when the CD4+ cell count was <250 cells/microL. Clinical outcomes in participants not receiving ART at entry inform the early use of ART. METHODS: Patients who were either ART naive (n=249) or who had not been receiving ART for >or= 6 months (n=228) were analyzed. The following clinical outcomes were assessed: (i) opportunistic disease (OD) or death from any cause (OD/death); (ii) OD (fatal or nonfatal); (iii) serious non-AIDS events (cardiovascular, renal, and hepatic disease plus non-AIDS-defining cancers) and non-OD deaths; and (iv) the composite of outcomes (ii) and (iii). RESULTS: A total of 477 participants (228 in the DC group and 249 in the VS group) were followed (mean, 18 months). For outcome (iv), 21 and 6 events occurred in the DC (7 in ART-naive participants and 14 in those who had not received ART for >or= 6 months) and VS (2 in ART-naive participants and 4 in those who had not received ART for 6 months) groups, respectively. Hazard ratios for DC vs. VS by outcome category were as follows: outcome (i), 3.47 (95% confidence interval [CI], 1.26-9.56; p=.02); outcome (ii), 3.26 (95% CI, 1.04-10.25; p=.04); outcome (iii), 7.02 (95% CI, 1.57-31.38; p=.01); and outcome (iv), 4.19 (95% CI, 1.69-10.39; p=.002 ). CONCLUSIONS: Initiation of ART at CD4+ cell counts >350 cells/microL compared with <250 cells/microL may reduce both OD and serious non-AIDS events. These findings require validation in a large, randomized clinical trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CD4+ Count–Guided Interruption of Antiretroviral Treatment
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa062360 · Cited by 2,231
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030218 · Cited by 1,678
Egger, M., May, M., Chêne, G., Phillips, A. N., Ledergerber, B., Dabis, F., Costagliola, D., Monforte, A. D., de Wolf, F., Reiss, P., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09411-4 · Cited by 1,525
Class of Antiretroviral Drugs and the Risk of Myocardial Infarction
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa062744 · Cited by 1,521
Self-citationLiver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus: The D:A:D Study
(2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1632 · Cited by 1,113
D'Cruz, D. P., Khamashta, M. A., & Hughes, G. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60279-7 · Cited by 992
Sterne, J. A., Hernán, M. A., Ledergerber, B., Tilling, K., Weber, R., Sendi, P., Rickenbach, M., Robins, J. M., & Egger, M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67022-5 · Cited by 557
The Strategies for Management of Antiretroviral Therapy (SMART) Study Group (2008) · The Journal of Infectious Diseases · doi:10.1086/529523 · Cited by 204
Self-citationWajed, J. (2004) · Rheumatology · doi:10.1093/rheumatology/keg436 · Cited by 169
Risk of cancers during interrupted antiretroviral therapy in the SMART study
Silverberg, M. J., Neuhaus, J., Bower, M., Gey, D., Hatzakis, A. E., Henry, K., Hidalgo, J. A. M., Lourtau, L., Neaton, J. D., Tambussi, G., et al. (2007) · AIDS · doi:10.1097/qad.0b013e3282ed6338 · Cited by 137
Lau, B. M., Gange, S. J., & Moore, R. D. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000247229.68246.c5 · Cited by 119
Podlekareva, D. N., Mocroft, A., Dragsted, U. B., Ledergerber, B., Beniowski, M., Lazzarin, A., Weber, J. N., Clumeck, N., Vetter, N., Phillips, A. N., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/506366 · Cited by 79
When should antiretroviral therapy for HIV be started?
Phillips, A. N., Gazzard, B., Clumeck, N., Losso, M. H., & Lundgren, J. D. (2007) · BMJ · doi:10.1136/bmj.39064.406389.94 · Cited by 74
Cited by
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
The INSIGHT START Study Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506816 · Cited by 2,798
Self-citationThompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa
The TEMPRANO ANRS 12136 Study Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507198 · Cited by 1,242
Self-citationEffect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
Kitahata, M. M., Gange, S. J., Abraham, A. G., Merriman, B., Saag, M. S., Justice, A. C., Hogg, R. S., Deeks, S. G., Eron, J. J., Brooks, J. T., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807252 · Cited by 1,105
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Metadata
- Authors
- The Strategies for Management of Antiretroviral Therapy (SMART) Study Group
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-04-15
- Volume
- 197
- Issue
- 8
- Pages
- 1133-1144
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W1574092316
- Cited by
- 399
- References
- 15
- FWCI
- 29.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.